Biovie Inc.
BIVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001580149
In the last 90 days, Biovie Inc. insiders filed 5 open-market purchases and 0 sales; 37 institutions reported holding it in 13F filings for Q2 2026, worth $2.86M in total; no superinvestor holds it.
Other share classesBIVIW
Key figures
- Market capClose on Nov 17, 2026
- $10.7M
- Insider buysLast 90 days, $52.0K in total
- 5
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 37
- 13F valueReported value at the end of Q2 2026
- $2.86M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- –
- No comparable prior period
- Net income, FY2026
- -$22.1M
- No comparable prior period
- Free cash flow, FY2026
- –
- No comparable prior period
- Revenue, Q1 FY2027
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 589.1K
- Shares sold short
- Change
- +44.6K
- +8.2% vs. previous
- Days to cover
- 3.68
- At average daily volume
Superinvestors holding BIVI, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding BIVI at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Biovie Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 (view filing)4:30 PM ET | Nov 13 | 3 days | Do Cuong VPresident & CEO | PPurchase | +2.50K | $1.16 | +$2.91K | +15.5%18.6K after | |
| Aug 28, 2026 (view filing)9:01 PM ET | Aug 28 | Same day | Palumbo Joseph MChief Medical Officer | PPurchase | +4.84K | $2.16 | +$10.5K | +406.0%6.04K after | |
| Aug 28, 2026 (view filing)9:01 PM ET | Aug 28 | Same day | Chappell Amy SuzonDirector | PPurchase | +727 | $2.16 | +$1.57K | New position727 after | |
| Aug 28, 2026 (view filing)8:58 PM ET | Aug 28 | Same day | Kim Joanne WendyChief Financial Officer | PPurchase | +2.50K | $2.18 | +$5.45K | +265.7%3.44K after | |
| Aug 28, 2026 (view filing)8:57 PM ET | Aug 27 | 1 day | Do Cuong VPresident & CEO | PPurchase | +15.2K | $2.08 | +$31.6K | +1,677.0%16.1K after | |
| Aug 13, 2025 (view filing) | Aug 7 | 6 daysLate | Do Cuong VPresident & CEO | PPurchase | +5.00K | – | – | +100.2%9.99K after | |
| Aug 13, 2025 (view filing) | Aug 7 | 6 daysLate | Do Cuong VPresident & CEO | PPurchase | +5.00K | – | – | –5.05K after | Derivative |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Do Cuong VPresident & CEO | PPurchase | +10.0K | – | – | +2.3%435.9K after | |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Do Cuong VPresident & CEO | PPurchase | +5.00K | – | – | –5.00K after | Derivative |
| Dec 6, 2023 (view filing) | Dec 1 | 5 daysLate | Gorlin SteveDirector | SSale | −75.7K | $1.69 | −$127.9K | −62.0%46.4K after |
Top 10 13F holders, Q2 2026
See all 37 holdersThe largest institutional positions in Biovie Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 605,471 | $1.17M | 0.00% | +530,250+704.9% | Added |
| Diametric Capital, LP | 256,636 | $497.9K | 0.05% | −113,364−30.6% | Reduced |
| Renaissance Technologies LLC | 127,918 | $248.2K | 0.00% | +60,000+88.3% | Added |
| Citadel Advisors LLC | 95,952 | $186.1K | 0.00% | +50,660+111.9% | Added |
| Vanguard Capital Management LLC | 70,906 | $137.6K | 0.00% | −13,161−15.7% | Reduced |
| Geode Capital Management, LLC | 70,752 | $137.3K | 0.00% | −13,451−16.0% | Reduced |
| Philadelphia Trust Co | 50,010 | $97.0K | 0.01% | −25,000−33.3% | Reduced |
| Vanguard Fiduciary Trust Co | 37,557 | $72.9K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 35,860 | $69.6K | 0.00% | +13,069+57.3% | Added |
| Prelude Capital Management, LLC | 32,583 | $63.2K | 0.00% | −59,480−64.6% | Reduced |
Holders of 5% or more of BIVI
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Biovie Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Acuitas Group Holdings, LLC | 13D/A | 15.80%3.05M shares | – | Jul 15, 20226 filings | Jun 30, 2025 | SEC |
| Morgan Stanley | 13G/A | 11.90%896.8K shares | +3.90 ppfrom 8.00% | Aug 7, 20262 filings | Aug 7, 2026 | SEC |
| Alta Partners LLC | 13G | 8.40%687.3K shares | New | Aug 19, 20261 filing | Aug 19, 2026 | SEC |
| Do Cuong V | 13D | 5.03%399.0K shares | New | Mar 25, 20261 filing | Mar 25, 2026 | SEC |